Aventis Pharmaceuticals Inc.

Ray Boffey

Hazel Joan Dyke

Charles J Gardner

Timothy A Gillespy

Elsa Amandine Dechaux

Sungtaek Lim

Bin Cao

Keith John Harris

David Stefany

Joacy C Aguiar

The present invention is directed to a compound of Formula (I) wherein Cy, Cy, L, L, and Rare as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists

Growing community of inventors

Harlow, United Kingdom

Ray Boffey